AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37898148
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least two doses of wild-type mRNA vaccine alone
Trial: 37898184
Drug: Ozanimod (OZA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod (OZA), oral, once daily, incremental dosage for a maximum of 14 days
Trial: 37898410
Drug: CS-2034 low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CS-2034 low-dose (30 μg of mRNA)
Trial: 37898410
Drug: CS-2034 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-2034 high-dose (50 μg of mRNA)
Trial: 37898410
Drug: Placebo (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.3 ml type 5 adenovirus vector for low-dose; 0.5 ml type 5 adenovirus vector for high-dose)
Trial: 37898741
Drug: At-home, self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home, self-administered COVID-19 testing kits distributed to participants.
Trial: 37898759
Drug: Cerebral oximetry
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral oximetry monitoring during mechanical ventilation according to SafeBoosC treatment guideline.
Trial: 37898781
Drug: mHealth-based self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth-based self-management intervention (AEGORA) via Sidekick app with weekly prompts
Trial: 37898781
Drug: mHealth-based self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth-based self-management intervention (AEGORA) via Sidekick app with monthly prompts
Trial: 37899297
Drug: Sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib plus triplet therapy with venetoclax, azacitidine, and homoharringtonine (VAH)
Trial: 37899433
Drug: High-dose pharmaceutical-grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pharmaceutical-grade biotin (100 mg taken orally three times a day over a maximum of 52 weeks)
Trial: 37899433
Drug: High-dose pharmaceutical-grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pharmaceutical-grade biotin
Trial: 37899826
Drug: ASP (iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP (iron supplement)
Trial: 37899826
Drug: FS administered
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS administered as a single weekly dose of 420 mg Fe
Trial: 37899826
Drug: FS administered
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS administered daily at 60 mg Fe/day
Trial: 37899826
Drug: FS plus
RxNorm normalized name: MILK THISTLE 6 [hp_X] in 1 mL / HELIANTHEMUM CANADENSE 6 [hp_X] in 1 mL / SOLANUM DULCAMARA TOP 6 [hp_X] in 1 mL / GALIUM APARINE 6 [hp_X] in 1 mL / MAGNESIUM CHLORIDE 6 [hp_X] in 1 mL / SODIUM SULFATE 6 [hp_X] in 1 mL / VISCUM ALBUM FRUITING TOP 6 [hp_X] in 1 mL / HYDROCHLORIC ACID 6 [hp_X] in 1 mL / ESTRONE 8 [hp_X] in 1 mL / SODIUM CHLORIDE 10 [hp_X] in 1 mL / AILANTHUS ALTISSIMA FLOWERING TWIG 12 [hp_X] in 1 mL / BARIUM CHLORIDE DIHYDRATE 12 [hp_X] in 1 mL / CADMIUM 12 [hp_X] in 1 mL / CEANOTHUS AMERICANUS LEAF 12 [hp_X] in 1 mL / ANAMIRTA COCCULUS SEED 12 [hp_X] in 1 mL / IRIDIUM 12 [hp_X] in 1 mL / THUJA OCCIDENTALIS LEAFY TWIG 12 [hp_X] in 1 mL / CINCHONA OFFICINALIS BARK 12 [hp_X] in 1 mL / OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X] in 1 mL / CROTALUS DURISSUS TERRIFICUS VENOM 16 [hp_X] in 1 mL ORAL LIQUID [EBV/CFS Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS plus a micronutrient powder (MNP) administered daily at 60 mg Fe/day
Trial: 37900876
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + Dry Needling (DN)
Trial: 37901358
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention using Nordic walking poles, personalized physician exercise prescriptions, pedometers, and access to exercise videos.
Trial: 37902726
Drug: BIIB080 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB080 (10 mg every 4 weeks, 30 mg every 4 weeks, 60 mg every 4 weeks, 115 mg every 12 weeks)
Trial: 37902726
Drug: BIIB080 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB080 (60 mg every 12 weeks, 115 mg every 12 weeks) during long-term extension
Trial: 37902732
Drug: Steady concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady concentration PD with 11 g/h glucose dose
Trial: 37902732
Drug: Steady concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady concentration PD with 14 g/h glucose dose
Trial: 37902732
Drug: Steady concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady concentration PD with 20 g/h glucose dose
Trial: 37902732
Drug: Standard 4-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 4-hour CAPD dwell with 2 L of 2.5% dextrose solution (control)
Trial: 37902814
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (standard support from their employer)
Trial: 37902861
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor signaling inhibitors (ARSi)
Trial: 37902990
Drug: Novel anti-NRP2
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Novel anti-NRP2 antibody
Trial: 37903153
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of oral hygiene
Trial: 37903324
Drug: Aspacytarabine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspacytarabine 4.5 g/m2 per day for 6 doses
Trial: 37903324
Drug: Aspacytarabine in
RxNorm normalized name: Aspacytarabine
DrugBank: Aspacytarabine (DB17226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspacytarabine in patients with prior treatment with hypomethylating agents
Trial: 37903325
Drug: Durvalumab before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab before JCAR014 infusion
Trial: 37903325
Drug: Ongoing durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing durvalumab therapy after JCAR014
Trial: 37903440
Drug: Antibiotics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics administered (2,296 antibiotic regimens; 95.7% intravenous, 4.3% oral)
Trial: 37903440
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed and administered on admission day
Trial: 37903440
Drug: Dosing accuracy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing accuracy of intravenous ciprofloxacin regimens
Trial: 37903440
Drug: Intravenous-to-oral switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous-to-oral switch
Trial: 37903440
Drug: Adult-dose tablets
RxNorm normalized name: hepatitis A vaccine (inactivated) strain HM175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult-dose tablets splitting
Trial: 37903465
Drug: Exogenous LH
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous LH administration during ovarian stimulation
Trial: 37903483
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517 (3 mg, 10 mg, or 20 mg)
Trial: 37903504
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab plus chemotherapy
Trial: 37903590
Drug: Atezolizumab (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (adjuvant treatment)
Trial: 37904082
Drug: 0.1% loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% loading dose for six months followed by 0.01% for six months (N=33)
Trial: 37904241
Drug: Haloperidol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2.5 mg IV every 8 hours, titrated up to 5 mg if delirium persisted until ICU discharge or up to 14 days
Trial: 37904247
Drug: TH-SC01 cells
RxNorm normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH-SC01 cells (120 million cells, single intralesional injection)
Trial: 37904250
Drug: Sirolimus (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (2 mg/day for 5-7 days)
Trial: 37904314
Drug: Seladelpar 5
RxNorm normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seladelpar 5 or 10 mg orally once daily
Trial: 37904861
Drug: Pain medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication intake
Trial: 37905356
Drug: Tablet fasted
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet fasted (100 mg peposertib)
Trial: 37905356
Drug: Tablet fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet fed (100 mg peposertib)
Trial: 37905356
Drug: OS fasted
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OS fasted (100 mg peposertib)
Trial: 37905421
Drug: 2-week patch
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week patch monitors for AF screening
Trial: 37906649
Drug: SOC Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC Chemotherapy + Trastuzumab (Arm C)
Trial: 37906726
Drug: Ofranergene obadenovec
RxNorm normalized name: Ofranergene obadenovec
DrugBank: Ofranergene obadenovec (DB15175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofranergene obadenovec (ofra-vec) with weekly paclitaxel
Trial: 37906726
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with weekly paclitaxel
Trial: 37907210
Drug: pyrotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrotinib (400 mg once daily) combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Trial: 37907210
Drug: placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Trial: 37907210
Drug: pyrotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrotinib (400 mg once daily)
Trial: 37907221
Drug: NIZ985 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIZ985 (1 µg/kg TIW)
Trial: 37907221
Drug: NIZ985 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIZ985 (1 µg/kg TIW) + spartalizumab (400 mg Q4W)
Trial: 37907221
Drug: NIZ985 (single-agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIZ985 (single-agent)
Trial: 37907482
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (i.v. thrombolysis)
Trial: 37907503
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Immunity-and-matrix-regulatory cells (IMRCs)
Trial: 37907503
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of umbilical cord MSCs (as a comparison)
Trial: 37907796
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg L-citrulline every 6 hours for 72 hours
Trial: 37907858
Drug: Multilevel mobility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel mobility intervention (information and exercise booklets, mobility diary, iPad with exercise videos, e-learning for healthcare professionals, oral presentation, mobility checklist, posters and pictures on the wards)
Trial: 37910157
Drug: Goal2Quit mobile
RxNorm normalized name: CHAMAEMELUM NOBILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal2Quit mobile app intervention with a 2-week sample of combination nicotine replacement therapy (NRT)
Trial: 37910157
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (self-help booklet for quitting smoking not tailored for depression)
Trial: 37910166
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (100 mg/kg body weight daily) with exercise (high-volume, moderate-intensity, whole-body exercise training 3 times per week for 8 weeks)
Trial: 37910313
Drug: Tenapanor (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenapanor (5 to 30 mg/dose, orally, twice-daily for 16 weeks)
Trial: 37910822
Drug: Pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab + Chemotherapy
Trial: 37910822
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Chemotherapy
Trial: 37913505
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg thalidomide
Trial: 37913505
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg thalidomide
Trial: 37913818
Drug: Arnica +
RxNorm normalized name: T-Relief Arnica +12 Plant-Based Relief Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnica + Standard Therapy (ST)
Trial: 37913818
Drug: Mucopolysaccharide Polysulfate
RxNorm normalized name: Mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucopolysaccharide Polysulfate (MPSP) + Standard Therapy (ST)
Trial: 37913936
Drug: Neuromodulators as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulators as solo therapy
Trial: 37913936
Drug: Prokinetics as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetics as solo new therapy
Trial: 37913936
Drug: Neuromodulators as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulators as solo new therapy with nondelayed gastric emptying
Trial: 37914482
Drug: Decitabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (20 mg/m²)
Trial: 37914482
Drug: 3+7 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3+7 chemotherapy
Trial: 37914594
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg once daily for 5 years
Trial: 37914976
Drug: NYM016 (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NYM016 (novel small-molecule PSMA-targeted fluorescence probe)
Trial: 37915337
Drug: eVCS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eVCS and retinol-bakuchiol serum (RBS) combination
Trial: 37915337
Drug: eVCS-RSB combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eVCS-RSB combination
Trial: 37915438
Drug: Mindfulness-based music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based music therapy (MBMT)
Trial: 37915546
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 100 mg bid + Selenium 100 mcg
Trial: 37915546
Drug: Resveratrol 350
RxNorm normalized name: Grape Seed Extract/Grape Skin Extract/Quercetin/Resveratrol 350 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 350 mg bid + TA-65 (Astragalus Membranaceus extract) 100U
Trial: 37915619
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid
Trial: 38411017
Drug: Control supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement containing calcium, iodine, iron, β-carotene, and folic acid
Trial: 37916028
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) once-weekly semaglutide
Trial: 37916303
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg administered twice daily for 8 weeks
Trial: 37916517
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with SBP target <120 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Trial: 37916517
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with SBP target <140 mmHg, TTR calculated based on SBP measurements during the first 3-month follow-up.
Trial: 37916620
Drug: Sibeprenlimab 2
RxNorm normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibeprenlimab 2 mg/kg
Trial: 37916620
Drug: Sibeprenlimab 4
RxNorm normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibeprenlimab 4 mg/kg
Trial: 37916620
Drug: Sibeprenlimab 8
RxNorm normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibeprenlimab 8 mg/kg
Trial: 37917058
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal.
Trial: 37917058
Drug: Dostarlimab treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab treatment.
Trial: 37917140
Drug: Twice-weekly outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly outpatient rehabilitation intervention (weekly physical and occupational therapy for 11 weeks)
Trial: 37917140
Drug: Twice-weekly outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly outpatient rehabilitation intervention
Trial: 37917187
Drug: Ivosidenib 500
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivosidenib 500 mg daily in 28-day cycles
Trial: 37917218
Drug: Bone targeted
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone targeted agents (BTAs)
Trial: 37917826
Drug: levcromakalim (50 µg/mL)
RxNorm normalized name: immunoglobulin G, human 50 MG/ML [Octagam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levcromakalim (50 µg/mL)
Trial: 37918404
Drug: DFMO (125-1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO (125-1,000 mg/m)
Trial: 37918674
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B supplementation (2 μg daily)
Trial: 37918790
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sevoflurane dose determined by anaesthesiologist)
Trial: 37919269
Drug: Chemo-immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy with oleclumab (arm A)
Trial: 37919269
Drug: Chemo-immunotherapy without
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy without oleclumab (arm B)
Trial: 37919438
Drug: corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid injection (CSI) (n=40)
Trial: 37919448
Drug: TPF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF chemotherapy followed by surgery
Trial: 37919456
Drug: TTV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTV DNA load < 4.05 log10 copies/ml at ICANS onset
Trial: 37919456
Drug: Falling or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Falling or stable TTV DNA load between lymphodepletion and CAR-T infusion
Trial: 37919483
Drug: ASC42 5-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC42 5-200 mg (SAD)
Trial: 37919483
Drug: ASC42 5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC42 5-50 mg (MAD) once-daily for 14 days
Trial: 37919483
Drug: ASC42 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC42 15 mg with a high-fat meal
Trial: 37919483
Drug: ASC42 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC42 (various doses)
Trial: 37919630
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin therapy (HNC)
Trial: 37919668
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg or 840 mg once daily with standard doses of everolimus for RCC
Trial: 37919668
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg or 840 mg once daily with standard doses of docetaxel for GC
Trial: 37919668
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg or 840 mg once daily with standard doses of cetuximab for CRC
Trial: 37919668
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg or 840 mg once daily
Trial: 37919695
Drug: Red blood
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red blood cell infusion
Trial: 37919697
Drug: Monthly Nuvaring®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly Nuvaring® (vaginal ring)